189 related articles for article (PubMed ID: 28029907)
1. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.
Altree-Tacha D; Tyrrell J; Haas T
Arch Pathol Lab Med; 2017 Jan; 141(1):144-150. PubMed ID: 28029907
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
3. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
4. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
5. [CK7, CK20, SOX10 and CDX2: expressions and diagnostic values in primary adenocarcinoma of the sinonasal tract].
Yue C; Piao Y; Bai Y; Liu H; Zhang L
Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(30):2447-50. PubMed ID: 26711206
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
[TBL] [Abstract][Full Text] [Related]
8. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
Park KJ; Bramlage MP; Ellenson LH; Pirog EC
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):8-11. PubMed ID: 18776815
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.
Ito R; Oue N; Yoshida K; Kunimitsu K; Nakayama H; Nakachi K; Yasui W
Virchows Arch; 2005 Oct; 447(4):717-22. PubMed ID: 16044349
[TBL] [Abstract][Full Text] [Related]
10. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
Saad RS; Silverman JF; Khalifa MA; Rowsell C
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
[TBL] [Abstract][Full Text] [Related]
11. CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin.
Ma H; Xiao W; Wang M; Shi X
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):541-545. PubMed ID: 33958523
[TBL] [Abstract][Full Text] [Related]
12. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract.
O'Connell FP; Wang HH; Odze RD
Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028
[TBL] [Abstract][Full Text] [Related]
13. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
Tot T
Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
[TBL] [Abstract][Full Text] [Related]
14. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
15. Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma.
Ortiz-Rey JA; Alvarez C; San Miguel P; Iglesias B; Antón I
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):142-6. PubMed ID: 15894926
[TBL] [Abstract][Full Text] [Related]
16. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
Park SY; Kim BH; Kim JH; Lee S; Kang GH
Arch Pathol Lab Med; 2007 Oct; 131(10):1561-7. PubMed ID: 17922593
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
[TBL] [Abstract][Full Text] [Related]
18. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
19. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
20. [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma].
Wang C; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):228-31. PubMed ID: 16776981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
